Liquidia Corporation

Good morning, and welcome everyone to the Liquida Corporation first quarter 2023 financial results and corporate update conference call. My name is Lisa, and I will be your conference operator today. Currently, all participants are in a listen-only mode. Following the presentation, we will conduct a question and answer session. Instructions will be provided at that time for you to queue up for questions. I would like to remind everyone that this conference call is being recorded. I will now hand the call over to Jason Adair, Senior Vice President, Corporate Development and Strategy. Please go ahead.

Thank you, Lisa. It's my pleasure to welcome everyone to Liquidia's first quarter 2023 Financial Results and Corporate Update conference call. Joining the call today are Chief Executive Officer Roger Jeffs, Chief Financial Officer Michael Cassetta, Chief Medical Officer Rajiv Sagar, Chief Commercial Officer Scott Mumaw, and General Counsel Rusty Schundler. Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results or performance to be materially different from any future results or performance expressed or implied on this call. For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website. I would now like to turn the call over to Roger for our prepared remarks, after which he will open up the call for your questions.

Thank you, Jason. Good morning, everyone, and thank you for joining us. As we said just seven weeks ago, our confidence remains high Our balance sheet is strong. Our legal team continues to have success in the courts and the market opportunity for Utropia. Our dry powder inhaled formulation of tryprosinil continues to expand as physicians gain better exposure to the benefits of inhaled prostacyclines in treating both PAH and PHILD patients. The PHILD opportunity is especially intriguing because it seems that the medical and investor communities at large are quickly catching up to the true value that can be created by finally offering an option to this previously untreated group. It's helpful to see the increasing demand for inhaled tryprosinol and the increased diagnosis and treatment of PHILD. It should accelerate adoption of Eutrefia given the clear benefits of tolerability, titratability, and overall patient experience with a low resistance device. While we wait for the opportunity to launch a product, we look forward to further defining Eutrefia's beneficial product profile in an open-label study in PHILD patients that we intend to initiate later this year. One of the reasons we decided to move up our earnings this quarter is to offer near real-time feedback on the most recent legal events that are gating to the potential approval and launch of Utrepia. I'd like to hand the call over to Rusty, who was just in the Federal Circuit Court yesterday for the oral arguments in the Hedge Waxman Appeals. Rusty.